Galapagos | GLPG - Operating Profit



Galapagos reported EUR-57027000 in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
argenx SE USD 203.84M 64.9M Jun/2025
AstraZeneca USD 3.51B 166M Jun/2025
Biogen USD 851.8M 540.6M Jun/2025
Genmab DKK 360M 172M Jun/2025
Gilead Sciences USD 2.7B 467M Jun/2025
GlaxoSmithKline GBP 2.02B 193M Jun/2025
GRIFOLS EUR 349.54M 80.68M Jun/2025
Hikma Pharmaceutical USD 282M 45M Dec/2024
Incyte USD 310.82M 105.66M Jun/2025
Merck EUR 1.03B 24M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Novartis USD 4.86B 201M Jun/2025
Roche Holding CHF 4.39B 1.04B Dec/2024
Sanofi EUR 1.71B 573M Jun/2025
UCB EUR 1B 678M Dec/2024
Vertex Pharmaceuticals USD 1.15B 123.1M Jun/2025